CN114008071B - 抗ctla-4结合蛋白及其使用方法 - Google Patents

抗ctla-4结合蛋白及其使用方法 Download PDF

Info

Publication number
CN114008071B
CN114008071B CN201980092796.9A CN201980092796A CN114008071B CN 114008071 B CN114008071 B CN 114008071B CN 201980092796 A CN201980092796 A CN 201980092796A CN 114008071 B CN114008071 B CN 114008071B
Authority
CN
China
Prior art keywords
ctla
seq
abp
antibody
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980092796.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114008071A (zh
Inventor
D·S·约翰逊
A·S·阿德勒
R·A·米兹拉希
林咏雯
M·艾森修
E·L·斯通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gigagen Inc
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Priority to CN202510014877.4A priority Critical patent/CN119930820A/zh
Publication of CN114008071A publication Critical patent/CN114008071A/zh
Application granted granted Critical
Publication of CN114008071B publication Critical patent/CN114008071B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980092796.9A 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法 Active CN114008071B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510014877.4A CN119930820A (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510014877.4A Division CN119930820A (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Publications (2)

Publication Number Publication Date
CN114008071A CN114008071A (zh) 2022-02-01
CN114008071B true CN114008071B (zh) 2025-01-21

Family

ID=71126610

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510014877.4A Pending CN119930820A (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法
CN201980092796.9A Active CN114008071B (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510014877.4A Pending CN119930820A (zh) 2018-12-27 2019-12-27 抗ctla-4结合蛋白及其使用方法

Country Status (12)

Country Link
US (1) US12421311B2 (enExample)
EP (1) EP3902821A4 (enExample)
JP (3) JP7558949B2 (enExample)
KR (1) KR20210121045A (enExample)
CN (2) CN119930820A (enExample)
AU (2) AU2019413366B2 (enExample)
BR (1) BR112021012588A2 (enExample)
CA (1) CA3124961C (enExample)
IL (2) IL284156B2 (enExample)
MX (1) MX2021007848A (enExample)
SG (1) SG11202106764YA (enExample)
WO (1) WO2020140084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201803359VA (en) * 2015-10-23 2018-05-30 Merus Nv Binding molecules that inhibit cancer growth
MX2021007848A (es) 2018-12-27 2021-10-26 Gigagen Inc Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
JP7783840B2 (ja) * 2020-07-02 2025-12-10 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質及びその使用方法
EP4271484A4 (en) * 2020-12-31 2025-01-15 NovaRock Biotherapeutics, Ltd. ANTIBODIES AGAINST TNFR2 AND USES THEREOF
EP4362981A1 (en) * 2021-07-02 2024-05-08 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459203A (zh) * 2014-06-06 2017-02-22 百时美施贵宝公司 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN107849144A (zh) * 2015-05-29 2018-03-27 艾吉纳斯公司 抗‑ctla‑4抗体及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) * 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
EP1793858A4 (en) * 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
PL2925350T3 (pl) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
WO2015092394A1 (en) 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
IL292578A (en) 2015-02-13 2022-06-01 Sorrento Therapeutics Inc Antibody therapeutics that bind ctla4
KR102740444B1 (ko) 2015-04-17 2024-12-10 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
HUE066907T2 (hu) * 2015-12-15 2024-09-28 Oncoc4 Inc Kiméra és humanizált anti-humán-CTLA4 monoklonális antitestek és alkalmazásaik
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
SG10202011219YA (en) 2017-02-27 2020-12-30 Dragonfly Therapeutics Inc Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
KR20230053001A (ko) * 2017-05-19 2023-04-20 우시 바이올로직스 (상하이) 컴퍼니 리미티드 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
MX2021007848A (es) 2018-12-27 2021-10-26 Gigagen Inc Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
WO2020154189A1 (en) 2019-01-21 2020-07-30 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
JP7783840B2 (ja) 2020-07-02 2025-12-10 ギガジェン，インコーポレイティッド 抗ｃｔｌａ－４結合タンパク質及びその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459203A (zh) * 2014-06-06 2017-02-22 百时美施贵宝公司 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
CN107849144A (zh) * 2015-05-29 2018-03-27 艾吉纳斯公司 抗‑ctla‑4抗体及其使用方法

Also Published As

Publication number Publication date
IL316757A (en) 2025-01-01
AU2019413366B2 (en) 2025-06-05
AU2025223772A1 (en) 2025-09-18
JP7558949B2 (ja) 2024-10-01
JP2025128343A (ja) 2025-09-02
KR20210121045A (ko) 2021-10-07
US12421311B2 (en) 2025-09-23
IL284156B2 (en) 2025-04-01
JP2024042072A (ja) 2024-03-27
CA3124961A1 (en) 2020-07-02
CN114008071A (zh) 2022-02-01
EP3902821A1 (en) 2021-11-03
SG11202106764YA (en) 2021-07-29
IL284156A (en) 2021-08-31
JP7745669B2 (ja) 2025-09-29
WO2020140084A1 (en) 2020-07-02
IL284156B1 (en) 2024-12-01
JP2022516071A (ja) 2022-02-24
MX2021007848A (es) 2021-10-26
BR112021012588A2 (pt) 2021-09-08
AU2019413366A1 (en) 2021-08-12
EP3902821A4 (en) 2022-11-30
CN119930820A (zh) 2025-05-06
CA3124961C (en) 2025-11-25
US20220064303A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CN114008071B (zh) 抗ctla-4结合蛋白及其使用方法
US20220064302A1 (en) Anti-PD-1 Binding Proteins and Methods of Use Thereof
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
US20220056137A1 (en) Anti-PD-L1 Binding Proteins and Methods of Use Thereof
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
CN117979995A (zh) 抗ctla-4结合蛋白及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant